

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

Nadia Bouabdallaoui ¹, Jean-Claude Tardif ^{1*}, David D. Waters ², Fausto J. Pinto ³, Aldo P. Maggioni⁴, Rafael Diaz⁵, Colin Berry ⁶, Wolfgang Koenig^{7,8,9}, Jose Lopez-Sendon¹⁰, Habib Gamra¹¹, Ghassan S. Kiwan¹², Lucie Blondeau ¹³, Andreas Orfanos ¹³, Reda Ibrahim¹, Jean C. Grégoire¹, Marie-Pierre Dubé¹, Michelle Samuel¹, Olivier Morel^{14,15}, Pascal Lim¹⁶, Olivier F. Bertrand¹⁷, Simon Kouz¹⁸, Marie-Claude Guertin¹³, Philippe L. L'Allier¹, and Francois Roubille ¹⁹

¹Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada and Université de Montréal, Montreal, Quebec, Canada; ²San Francisco General Hospital, California; ³Santa Maria University Hospital (CHULN), CAML, CCUL, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; ⁴ANMCO Research Center, Firenze, Italy; ⁵Estudios Clínicos Latinoamerica, Rosario, Argentina; ⁶University of Glasgow and NHS Glasgow Clinical Research Facility, Glasgow, UK; ⁷Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; ⁸DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; ⁹Institute of Epidemiology and Medical Biometry, University of Ulm, Germany; ¹⁰H La Paz, IdiPaz, UAM, Ciber-CV Madrid, Spain; ¹¹Fattouma Bourguiba University Hospital, Monastir, Tunisia; ¹²Bellevue Medical Center, Beirut, Lebanon; ¹³The Montreal Health Innovations Coordinating Center (MHICC), Montreal, Canada; ¹⁴Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France; ¹⁵INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France; ¹⁶Department of Cardiology, AP-HP, Hôpital Universitaire Henri-Mondor and INSERM U955, Université Paris-Est Créteil, Créteil, France; ¹⁷Institut de Cardiologie et Pneumologie de Québec, Quebec City, Canada; ¹⁸Centre Hospitalier Régional de Lanaudière, Joliette, Canada; and ¹⁹Université de Montpellier, INSERM, CNRS, CHU de Montpellier, France;

Received 1 July 2020; revised 15 July 2020; editorial decision 27 July 2020; accepted 28 July 2020

Aims

The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine.

Methods and results

In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4–7 and >8 days) was examined using multivariable Cox regression models. Amongst the 4661 patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata. After a median follow-up of 22.7 months, there was a significant reduction in the incidence of the primary endpoint for patients in whom colchicine was initiated < Day 3 compared with placebo [hazard ratios (HR) = 0.52, 95% confidence intervals (CI) 0.32–0.84], in contrast to patients in whom colchicine was initiated between Days 4 and 7 (HR = 0.96, 95% CI 0.53–1.75) or > Day 8 (HR = 0.82, 95% CI 0.61–1.11). The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35),

* Corresponding author. Email: jean-claude.tardif@icm-mhi.org

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke (HR = 0.55, all $P < 0.05$).

Conclusion



Patients benefit from early, in-hospital initiation of colchicine after MI.

Trial Registration

COLCOT ClinicalTrials.gov number, NCT02551094.

Graphical Abstract

COLCOT: Early initiation of low-dose colchicine after myocardial infarction reduces the risk of ischemic CV events by 48% compared with placebo.



Keywords

Cardiovascular inflammation • Time-to-treatment initiation • Colchicine • COLCOT • Inflammasome

Introduction

Myocardial infarction (MI) is associated with an acute exacerbation of cardiovascular (CV) inflammation superimposed on the chronic atherosclerosis-related inflammatory process.¹ Intense inflammation observed at the time of an acute MI has been shown to be involved in the pathogenesis of post-infarction remodelling, with NLRP3 inflammasome activation playing a particularly important and deleterious role in this setting.^{2–5} Colchicine is an inexpensive, orally administered, potent anti-inflammatory medication that was initially extracted from the plant autumn crocus. Its mechanism of action is through the inhibition of tubulin polymerization leading to effects on cellular adhesion molecules, inflammatory chemokines, and the inflammasome.^{6–8} Colchicine at the low dose of 0.5 mg daily was shown to significantly reduce the risk of ischaemic CV events by 23% compared with placebo when initiated

within the first 30 days after MI in the COLchicine Cardiovascular Outcomes Trial (COLCOT).⁹

Whether the timing of inflammation reduction after MI has a clinical impact is not known. Specifically, the importance of initiating colchicine immediately during the hospitalization for MI remains to be determined. We hypothesized that early initiation of inflammation reduction with colchicine is associated with greater clinical benefits after MI. Therefore, we aimed to determine whether TTI of colchicine influenced its beneficial impact on CV outcomes in COLCOT.

Methods

Study design and patient population

COLCOT was an international multicentre, randomized, double-blinded trial that randomly assigned patients to receive either low-dose colchicine




Figure 1 Subject disposition, flow chart diagram.

(0.5 mg once daily) or placebo. The study protocol and main results have been published.⁹ Patients were considered eligible if they had a recent MI (<30 days). Main exclusion criteria were severe heart failure, reduced left ventricular ejection fraction (<35%), recent stroke (<3 months), type 2 MI, recent (<3 years), or planned coronary artery bypass graft (CABG), history of cancer (<3 years), and inflammatory bowel disease or chronic diarrhoea. All patients enrolled in the trial benefitted from percutaneous coronary intervention whenever indicated and guidelines-directed management of CV disease prior to randomization.⁹ Clinical follow-up consisted of evaluations at 1 and 3 months after randomization and every 3 months thereafter. An independent clinical endpoint committee, blinded to trial-group assignment, adjudicated clinical endpoints. The trial was locally approved by the various institutional review boards, and all patients signed a written informed consent before enrolment.⁹

Efficacy endpoints

The primary efficacy endpoint was a composite of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The secondary endpoints consisted of the components of the primary efficacy endpoint, all-cause death, and a composite of CV death, resuscitated cardiac arrest, MI, or stroke.⁹ Exploratory endpoints included all coronary revascularizations, including both elective and urgent coronary revascularizations.⁹

Cut-offs for time-to-treatment initiation of colchicine

Three different cut-offs for TTI were used in order to determine the association between early initiation of therapy and clinical outcomes. These cut-offs were determined based on the usual journey of patients with MI.^{10,11} The first 30-day post-MI timeline was divided into three independent periods of time and analysed as such: from Day 0 to 3, referring to in-hospital management; from Day 4 to 7, referring to early post-discharge period, and from Day 8 to 30, referring to late post-discharge period.

Statistical analysis

Data were centrally analysed by an independent academic biostatistics centre at the Montreal Health Innovations Coordinating Center.⁹ The present analysis was conducted amongst patients who received at least one dose of the study medication (referred to as the safety population in the main protocol,⁹ Figure 1). Time-to-treatment initiation was defined as the length of time in days between the index MI and the initiation of the study medication, and three specific cut-offs were analysed (\leq Day 3, Days 4 to 7, and \geq Day 8). Early initiation of therapy was defined as TTI ≤ 3 days. Baseline characteristics were summarized using counts and percentages for categorical variables and mean \pm standard deviation (SD) for continuous variables. For each baseline characteristic, comparisons were made using ANOVA for continuous variables and Chi-Square test for categorical variables according to TTI strata. Analyses of the efficacy endpoints, expressed as time to event, were conducted according to TTI. Adjusted hazard ratios (HR) along with 95% confidence intervals (CI) were calculated from stepwise multivariable Cox regression models adjusted for the same covariates that were used in the main analysis of the COLCOT trial.⁹ All statistical tests were two-sided and conducted at the 0.05 significance level. Statistical analyses were performed with the use of SAS software, version 9.4 (SAS Institute).

Results

Baseline characteristics

Of the 4745 patients randomized in COLCOT, 4661 were included in the present analysis (colchicine, $N = 2322$; placebo, $N = 2339$) (Figure 1). Overall, patients were randomized at 13.5 ± 10.1 days following the index MI, 25.6% between Days 0 and 3, 15.4% between Days 4 and 7 and 59.0% at Day 8 or after. Baseline characteristics were similar between the colchicine and placebo groups (Table 1). Patients were mostly men (81.0%) with a mean age of 60.5 years, 20.2% had diabetes, 51.0% had a history of hypertension, 29.7% were active smokers, and 16.8% had had a prior percutaneous coronary intervention (PCI). Background therapy included aspirin, a second

Table 1 Baseline characteristics according to treatment allocation

Characteristics	All patients (N = 4661)	Colchicine group (N = 2322)	Placebo group (N = 2339)
Age (years), mean ± SD	60.5 ± 10.6	60.6 ± 10.6	60.5 ± 10.6
Male sex, no. (%)	3774 (81.0%)	1861 (80.1%)	1913 (81.8%)
BMI (kg/m ²), mean ± SD	28.3 ± 4.7	28.2 ± 4.8	28.4 ± 4.7
Current smoking, no./total no. (%)	1382/4659 (29.7)	694/2322 (29.9%)	688/2337 (29.4%)
History of hypertension, no. (%)	2377 (51.0)	1160 (50.0)	1217 (52.0)
History of diabetes, no. (%)	942 (20.2)	451 (19.4)	491 (21.0)
Prior MI, no. (%)	751 (16.1)	360 (15.5)	391 (16.7)
Prior PCI, no. (%)	783 (16.8)	382 (16.5)	401 (17.1)
Prior CABG, no. (%)	146 (3.1)	66 (2.8)	80 (3.4)
Prior HF, no. (%)	90 (1.9)	48 (2.1)	42 (1.8)
Prior stroke or TIA, no. (%)	119 (2.6)	53 (2.3)	66 (2.8)
PCI associated with the index event, no. (%)	4336 (93.0)	2154 (92.8)	2182 (93.3)
Medication use, no. (%):			
Aspirin	4605 (98.8)	2291 (98.7)	2314 (98.9)
Other anti-platelet agent	4567 (98.0)	2267 (97.6)	2300 (98.3)
Statin	4615 (99.0)	2297 (98.9)	2318 (99.1)
Beta-blocker	4143 (88.9)	2077 (89.4)	2066 (88.3)
TTI 0–3 days, no. (%)	1193 (25.6)	604 (26.0)	589 (25.2)
TTI 4–7 days, no. (%)	720 (15.4)	364 (15.7)	356 (15.2)
TTT ≥8 days, no. (%)	2748 (59.0)	1354 (58.3)	1394 (59.6)
Time from index MI to randomization (days), mean ± SD	13.5 ± 10.1	13.5 ± 10.1	13.5 ± 10.0
Time from Index MI to PCI (days), mean ± SD	1.4 ± 2.9	1.4 ± 2.9	1.4 ± 2.9
Time from PCI to randomization (days), mean ± SD	11.9 ± 9.9	11.9 ± 9.9	11.9 ± 9.9

Data were missing on the following characteristics: age (assessed according to date of birth; see below) for 431 patients (213 in the colchicine group and 218 in the placebo group) and body-mass index (the weight in kilograms divided by the square of the height in meters) for 5 (1 and 4 patients, respectively).

Date of birth was not required field because it was considered in some countries to be sensitive data that could allow for the identification of patients.

For statistical reporting, missing information regarding the day of birth was replaced by 15, and missing information regarding the month and day of birth was replaced by 1 July. CABG, coronary artery bypass graft surgery; HF, heart failure; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

anti-platelet agent and a statin in 98.8%, 98.0%, and 99.0% of patients, respectively. The vast majority of patients (93.0%) underwent PCI during the index hospitalization, with no difference in terms of time to PCI between the two groups.

Baseline characteristics according to TTI strata are shown in Table 2. Patients in whom therapy was initiated between Days 0 and 3, when compared with those at Days 8–30, were younger (59.1 ± 10.8 vs. 61.3 ± 10.4 years) and more often active smokers (43.8% vs. 20.2%), had less commonly hypertension (41.1% vs. 56.2%), and diabetes (17.4% vs. 22.0%) but underwent more often PCI associated with the index MI (95.8% vs. 91.3%), all $P < 0.05$.

Effects of time-to-treatment initiation on the primary efficacy endpoint

The effects of colchicine on the primary endpoint according to TTI are shown in Table 3 and Figure 2. A primary endpoint event occurred in 4.3% of patients in the colchicine group, as compared with 8.3% of those in the placebo group when TTI was between Days 0 and 3 ($N = 1193$, HR = 0.52, 95% CI 0.32–0.84, $P = 0.007$, Figure 3A). Corresponding rates were 6.0% and 5.9% when TTI was between

Days 4 and 7 ($N = 720$) and 5.7% and 7.1% when TTI was on Day 8 or after ($N = 2748$), but these differences between groups did not reach statistical significance. Table 3 also shows the percentages of patients with events and the hazard ratios for the components of the primary endpoint, including CV death (HR = 1.04, 95% CI 0.15–7.37), resuscitated cardiac arrest (HR = 0.33, 95% CI 0.03–3.20), MI (HR = 0.58, 95% CI 0.32–1.05), stroke (HR = 0.21, 95% CI 0.02–1.81), and urgent hospitalization for angina requiring coronary revascularization (HR = 0.35, 95% CI 0.14–0.88).

Effects of time-to-treatment initiation on the secondary and exploratory efficacy endpoints

The effects of colchicine on the secondary and exploratory endpoints are shown in Table 3. The secondary efficacy endpoint consisting of a composite of CV death, cardiac arrest, MI, or stroke occurred in 3.3% of the patients in the colchicine group and in 6.1% of those in the placebo group when TTI was between Days 0 and 3 (HR = 0.55; 95% CI, 0.32–0.95, Figure 3B). The exploratory endpoint of all coronary revascularizations occurred in 5.5% of patients in the colchicine

Table 2 Baseline characteristics according to time-to-treatment initiation

Characteristics	TTI 0–3 days (N = 1193)	TTI 4–7 days (N = 720)	TTT ≥ 8 days (N = 2748)	P ^a	P ^b
Age (years), mean ± SD	59.1 ± 10.8	60.1 ± 11.0	61.3 ± 10.4	<0.0001	<0.0001
Male sex, no. (%)	980 (82.2)	605 (84.0)	2189 (80.0)	0.014	0.071
BMI (kg/m ²), mean ± SD	28.1 ± 4.6	27.7 ± 4.6	28.6 ± 4.8	<0.0001	0.004
Current smoking, no. (%)	522 (43.8)	306 (42.6)	554 (20.2)	<0.0001	<0.0001
History of hypertension, no. (%)	490 (41.1)	343 (47.6)	1544 (56.2)	<0.0001	<0.0001
History of diabetes, no. (%)	208 (17.4)	130 (18.1)	604 (22.0)	0.001	0.001
Prior MI, no. (%)	170 (14.3)	111 (15.4)	470 (17.1)	0.070	—
Prior PCI, no. (%)	182 (15.3)	107 (14.9)	494 (18.0)	0.035	0.037
Prior CABG, no. (%)	34 (2.9)	30 (4.2)	82 (3.0)	0.218	—
Prior HF, no. (%)	14 (1.2)	12 (1.7)	64 (2.3)	0.046	0.017
Prior stroke or TIA, no. (%)	20 (1.7)	21 (2.9)	78 (2.8)	0.084	—
PCI associated with the index event, no. (%)	1143 (95.8)	685 (95.1)	2508 (91.3)	<0.0001	<0.0001
Medication use, no. (%)					
Aspirin	1181 (99.0)	715 (99.3)	2709 (98.6)	0.219	—
Other anti-platelet agent	1177 (98.7)	708 (98.3)	2682 (97.6)	0.072	—
Statin	1188 (99.6)	708 (98.3)	2719 (98.9)	0.024	0.047
Beta-blocker	1093 (91.6)	642 (89.2)	2408 (87.6)	0.001	0.0003
Time from index MI to randomization (days), mean ± SD	2.1 ± 0.8	5.1 ± 1.1	20.8 ± 6.6	—	—
Time from index MI to PCI (days), mean ± SD	0.4 ± 0.7	1.4 ± 1.8	1.8 ± 3.6	<0.0001	<0.0001
Time from PCI to randomization (days), mean ± SD	1.6 ± 0.9	3.7 ± 1.9	18.8 ± 7.3	<0.0001	<0.001

Data were missing on the following characteristics: age (assessed according to date of birth; see below) for 431 patients (213 in the colchicine group and 218 in the placebo group) and body-mass index (the weight in kilograms divided by the square of the height in meters) for 5 (1 and 4 patients, respectively).

Date of birth was not a required field because it was considered in some countries to be sensitive data that could allow for the identification of patients. For statistical reporting, missing information regarding the day of birth was replaced by 15, and missing information regarding the month and day of birth was replaced by 1 July.

CABG, coronary artery bypass graft surgery; HF, heart failure; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

^aGroup comparison TTI 0–3 vs. TTI 4–7 vs. TTI ≥ 8 days.

^bGroup comparison TTI 0–3 vs. TTI ≥ 8 days.

group, as compared with 8.7% of those in the placebo group when TTI was between Days 0 and 3 (HR = 0.63, 95% CI 0.40–0.97). There were six deaths in both study groups when TTI was between Days 0 and 3 (HR = 1.03, 95% 0.33–3.19).

Discussion

This analysis of COLCOT shows that early initiation of low-dose colchicine within the first 3 days after MI is associated with a reduction of 48% in the risk of the primary endpoint consisting of a composite of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization, in comparison with placebo. This result was due to a lower incidence of MIs, strokes, and urgent hospitalizations for angina leading to coronary revascularization. The secondary efficacy endpoint consisting of a composite of CV death, resuscitated cardiac arrest, MI, or stroke was also significantly reduced by 45% with early initiation of low-dose colchicine. The benefits were more marked when treatment was initiated within the first 3 days after MI, as compared with between Days 4 and 30, supporting the strategy of in-hospital initiation of colchicine in order to improve CV outcomes post-MI.

Acute inflammatory response following myocardial infarction

Convincing evidence converge towards inflammation as a key factor in CV disease progression and exacerbation.¹² In the acute phase of MI, cardiomyocyte necrosis generates damage-associated molecular patterns, which in turn activate the complement cascade and stimulate toll-like receptor and interleukin-1 signalling.^{13,14} These factors trigger an intense inflammatory response that may lead to adverse myocardial remodelling⁴ and in which activated inflammasomes within myocardial fibroblasts play a crucial role.^{2,3,5} Furthermore, an acute systemic inflammation response has been demonstrated in patients with recent MI^{15,16} and associated with infarct size.¹⁷ Colchicine binds to tubulin and prevents microtubule polymerization, consequently reducing inflammasome activation and pro-inflammatory cytokine release. Colchicine concentrates preferentially in white blood cells, thus exerting its anti-inflammatory effects even at low doses.¹⁸ The importance of early initiation of colchicine on CV outcomes after MI in COLCOT is compatible with an effect on innate immune cells.¹⁷ Short-term anti-inflammatory therapy with colchicine was also associated with smaller infarct size and reduced inflammatory response in a pilot study of patients with STEMI undergoing primary PCI.¹⁹

Table 3 Efficacy endpoints according to time-to-treatment initiation (N = 4661, colchicine vs. placebo)

Endpoints	TTI 0–3 days, N = 1193	TTI 4–7 days, N = 720	TTI ≥ 8 days, N = 2748
	Colchicine vs. placebo, no. (%) HR (95% CI); P	Colchicine vs. placebo, no. (%) HR (95% CI); P	Colchicine vs. placebo, no. (%) HR (95% CI); P
Primary composite endpoint	26 (4.3%) vs. 49 (8.3%) 0.52 (0.32–0.84); P = 0.007	22 (6.0%) vs. 21 (5.9%) 0.96 (0.53–1.75); P = 0.896	77 (5.7%) vs. 99 (7.1%) 0.82 (0.61–1.11); P = 0.200
CV death	2 (0.3%) vs. 2 (0.3%) 1.04 (0.15–7.37); P = 0.970	2 (0.5%) vs. 4 (1.1%) 0.45 (0.08–2.46); P = 0.356	15 (1.1%) vs. 18 (1.3%) 0.89 (0.45–1.76); P = 0.734
Resuscitated cardiac arrest	1 (0.2%) vs. 3 (0.5%) 0.33 (0.03–3.20); P = 0.340	2 (0.5%) vs. 1 (0.3%) 1.90 (0.17–20.95); P = 0.600	2 (0.1%) vs. 2 (0.1%) 1.02 (0.14–7.22); P = 0.986
MI	17 (2.8%) vs. 29 (4.9%) 0.58 (0.32–1.05); P = 0.071	16 (4.4%) vs. 9 (2.5%) 1.67 (0.74–3.78); P = 0.218	52 (3.8%) vs. 59 (4.2%) 0.93 (0.64–1.35); P = 0.710
Stroke	1 (0.2%) vs. 5 (0.8%) 0.21 (0.02–1.81); P = 0.156	1 (0.3%) vs. 3 (0.8%) 0.28 (0.03–2.71); P = 0.272	2 (0.1%) vs. 11 (0.8%) 0.19 (0.04–0.84); P = 0.029
Urgent hospitalization for angina requiring coronary revascularization	6 (1.0%) vs. 17 (2.9%) 0.35 (0.14–0.88); P = 0.026	4 (1.1%) vs. 6 (1.7%) 0.63 (0.18–2.24); P = 0.476	15 (1.1%) vs. 26 (1.9%) 0.61 (0.32–1.16); P = 0.131
Secondary composite endpoint	20 (3.3%) vs. 36 (6.1%) 0.55 (0.32–0.95); P = 0.031	18 (4.9%) vs. 16 (4.5%) 1.04 (0.53–2.03); P = 0.919	67 (4.9%) vs. 77 (5.5%) 0.92 (0.66–1.28); P = 0.629
All-cause death	6 (1.0%) vs. 6 (1.0%) 1.03 (0.33–3.19); P = 0.962	8 (2.2%) vs. 7 (2.0%) 1.03 (0.37–2.84); P = 0.957	26 (1.9%) vs. 31 (2.2%) 0.90 (0.53–1.51); P = 0.684
All coronary revascularizations	33 (5.5%) vs. 51 (8.7%) 0.63 (0.40–0.97); P = 0.037	25 (6.9%) vs. 18 (5.1%) 1.41 (0.76–2.61); P = 0.275	72 (5.3%) vs. 94 (6.7%) 0.81 (0.59–1.10); P = 0.172

The primary composite endpoint included CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The secondary composite endpoint included CV death, resuscitated cardiac arrest, MI, and stroke. Only the initial event was counted in the analyses of time to first event for the primary composite endpoint and for the secondary composite endpoint.

Covariates included in the stepwise multivariable Cox regression models are: age; sex; BMI; smoking status; history of diabetes; history of hypertension; history of dyslipidaemia; prior MI; prior coronary revascularization (prior PCI or prior CABG); prior heart failure. All models also included TTI, group and the interaction between group and TTI. CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; HR, hazard ratio; PCI, percutaneous coronary intervention; TTI, time-to-treatment initiation.




Figure 2 Associations between time-to-treatment initiation and the risk of occurrence of the primary composite endpoint. The adjusted hazard ratio and 95% confidence intervals come from a quadratic multivariable Cox regression model.

The benefit of colchicine in reducing the risk of stroke was large in COLCOT, which supports the favourable vascular effects of inflammation reduction with this medication. Whether there is a particular effect of colchicine on the cerebral vascular bed is unknown. In contrast, there was no significant impact of colchicine on the incidence of atrial fibrillation in COLCOT.

Targeting residual cardiovascular risk with anti-inflammatory therapy

Inflammation contributes to all phases of atherosclerotic disease, and recent data from randomized trials have provided novel insights into the role of inflammation modulation for CV risk reduction.²⁰ The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) of patients with stable coronary disease demonstrated that the selective IL-1 β inhibitor canakinumab yielded a reduction of 15% in the risk of a CV event,²¹ which was correlated with the lowering of inflammation biomarker levels.²² The main COLCOT results revealed that colchicine reduced the risk of ischaemic CV events by 23% in the post-MI setting.⁹ Results from the present COLCOT analysis suggest that early suppression of inflammation after MI provides




Figure 3 Kaplan–Meier event curves for the primary and secondary efficacy composite endpoints in the colchicine group and the placebo group according to time-to-treatment initiation. The inset shows the same data on an enlarged y-axis. (A) Cumulative incidence of the primary composite endpoint in patients with time-to-treatment initiation ≤ 3 days; (B) Cumulative incidence of the secondary composite endpoint in patients with time-to-treatment initiation ≤ 3 days.

even greater benefits, with a reduction of 48% in the risk of the composite primary endpoint when colchicine was initiated between Days 0 and 3. The demonstrated cost-effectiveness of low-dose colchicine also supports its large-scale use after MI.²³ Results of the LoDoCo2²⁴ study of patients with stable coronary artery disease will complement those of COLCOT in the post-MI setting.

Limitations

This analysis has limitations. Time-to-treatment initiation was analysed using three strata chosen according to the usual journey of patients with uncomplicated MI. A larger trial might have allowed a better assessment of individual endpoints and subgroups.

Conclusions

Early initiation of low-dose colchicine after MI greatly reduced the risk of ischaemic CV events compared with placebo. These results support in-hospital initiation of adjunctive anti-inflammatory therapy with colchicine for post-MI prevention.

Acknowledgements

The COLCOT trial was supported by the Government of Quebec, the Canadian Institutes of Health Research, the Montreal Heart Institute Foundation and other philanthropic foundations. We thank the trial investigators and co-ordinators at all the centres; trial monitors and staff from the Montreal Health Innovations Coordinating Center, including Gabriela Stamatescu, MD, Otilia Goga, MD, and Ourida Mehenni Hadjeres, MD, for medical review; Ève Roy-Clavel, MSc, CMC, Andrée Brunelle, BA, and Luc Dion, MSc, for data management and programming; Sylvie Lévesque, MSc, Anna Nozza, MSc, Mariève Cossette, MSc, Annik Fortier, MSc, and Daniel Cournoyer, MSc, for assistance with biostatistics; and Randa Zamrini, BSc,

Marianne Rufiange, PhD, Andréa Alicia Dumont, BSc, Mylène Provencher, PhD, and Zohar Bassevitch, BSc, for clinical operations; and the participating patients for their contribution to the trial.

Funding

The COLCOT trial was supported by the Government of Quebec, the Canadian Institutes of Health Research, the Montreal Heart Institute Foundation and other philanthropic foundations. The funding sources had no role in study design, conduct, or analyses.

Conflict of interest: N.B. reports personal fees from AstraZeneca, outside the submitted work; J.-C.T. reports grants from Government of Quebec, Canadian Institutes of Health Research, Montreal Heart Institute Foundation, during the conduct of the study; grants from Amarin, grants and personal fees from AstraZeneca, grants, personal fees and other from Dalcor, grants from Esperion, Ionis, grants and personal fees from Sanofi, Servier, grants from RegenXBio, outside the submitted work; In addition, J.-C.T. has a patent Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent pending, a patent Methods for using low-dose colchicine after MI pending to Invention assigned to the Montreal Heart Institute, and a patent Methods of treating a coronavirus infection using Colchicine pending; D.D.W. reports personal fees from Pharmascience, outside the submitted work; F.J.P. has nothing to disclose; A.P.M. reports personal fees from Bayer, Fresenius, and Novartis, outside the submitted work; R.D. reports grants from MHIRC, during the conduct of the study; grants from DALCOR, outside the submitted work; C.B. has nothing to disclose; W.K. reports personal fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor, Kowa, Amgen, Corvidia, Daiichi-Sankyo, Berlin-Chemie, Sanofi, and Bristol-Myers Squibb, grants and non-financial support from Singulex, Abbott, Roche Diagnostics, and Beckmann, outside the submitted work; J.L.-S. reports grants from Montreal Heart Institute, during the conduct of the study; grants from Bayer, Pfizer, Sanofi, and Boehringer Ingelheim, outside the submitted work; H.G. has nothing to disclose; G.S.K. receiving lecture fees from Bayer, Servier, Novartis, AstraZeneca, Bristol-Myers Squibb, Roche, and Pfizer; L.B., A.O., R.I., and J.C.G. have nothing to

disclose; M.-P.D. reports grants from Government of Quebec, during the conduct of the study; personal fees from Dalcor, personal fees and other from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, and Sanofi, outside the submitted work; In addition, M.-P.D. has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor, no royalties received, a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor, no royalties received, and a patent Methods for using low-dose colchicine after MI with royalties paid to Invention assigned to the Montreal Heart Institute; M.S., O.M., P.L., and O.F.B. have nothing to disclose; S.K. reports personal fees and other from Medtronic, grants, personal fees and other from Sanofi, other from Johnson & Johnson, personal fees and other from Amgen, grants, personal fees and other from AstraZeneca and Novartis, other from Celgene, Biogen, Gilead, Roche, and Boston Scientific, personal fees and other from Bausch Health, other from GSK, personal fees and other from BMS, other from TG Therapeutics, Becton Dickinson, and Spectrum Pharmaceuticals, personal fees from Merck, Eli Lilly, Pfizer, and Bayer, grants and personal fees from Boehringer-Ingelheim, personal fees from Servier, grants from Esperion, Dalcor, Eisai, Amarin, and Theracos, outside the submitted work; M.-C.G. and P.L.L. have nothing to disclose; F.R. reports grants, personal fees and non-financial support from AIR LIQUIDE, grants and personal fees from ABBOTT, personal fees from VIFOR, grants and personal fees from NOVARTIS, personal fees from Servier, Abiomed, and Zoll, grants and personal fees from ASTRA ZENECA, personal fees from Medtronic, personal fees from Resmed, from LVL, Eole, personal fees from Pfizer, outside the submitted work.

References

- Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. *N Engl J Med* 1994;**331**:417–424.
- Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. *Circulation* 2011;**123**:594–604.
- Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. *J Am Coll Cardiol* 2016;**67**:2050–2060.
- Chen B, Frangogiannis NG. Immune cells in repair of the infarcted myocardium. *Microcirculation* 2017;**24**:e12305.
- Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, Yang H, Xiang H, Yang J, Xu L, Tang Y. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. *Int Immunopharmacol* 2019;**74**:105575.
- Perico N, Ostermann D, Bontempoill M, Morigi M, Amuchastegui CS, Zoja C, Akalin E, Sayegh MH, Remuzzi G. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. *J Am Soc Nephrol* 1996;**7**:594–601.
- Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* 2004;**428**:198–202.
- Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. *Arthritis Rheum* 2007;**56**:3183–3188.
- Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie M-A, Dubé M-P, Rhoads D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin M-C, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med* 2019;**381**:2497–2505.
- Topol EJ, Burek K, O'Neill WW, Kewman DG, Kander NH, Shea MJ, Schork MA, Kirscht J, Juni JE, Pitt B. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. *N Engl J Med* 1988;**318**:1083–1088.
- Tran HV, Lessard D, Tsiminetzky MS, Yarzebski J, Granillo EA, Gore JM, Goldberg R. Trends in length of hospital stay and the impact on prognosis of early discharge after a first uncomplicated acute myocardial infarction. *Am J Cardiol* 2018;**121**:397–402.
- Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, Hasan AA, Amar S. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. *J Am Coll Cardiol* 2018;**72**:2071–2081.
- Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodeling. *Nat Rev Cardiol* 2014;**11**:255–265.
- Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. *Circ Res* 2016;**119**:91–112.
- Mollmann H, Nef HM, Kostin S, von Kalle C, Pilz I, Weber M, Schaper J, Hamm CW, Elsasser A. Bone marrow-derived cells contribute to infarct remodeling. *Cardiovasc Res* 2006;**71**:661–671.
- Frangogiannis NG. Chemokines in ischemia and reperfusion. *Thromb Haemost* 2007;**97**:738–747.
- Husser O, Bodi V, Sanchis J, Nunez J, Mainar L, Chorro FJ, Lopez-Lereu MP, Monmeneu JV, Chaustre F, Forteza MJ, Trapero I, Dasi F, Benet I, Riegger GA, Llacer A. White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance-derived infarct size and impact on outcome. *Inflammation* 2011;**34**:73–84.
- Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. *Rheumatology (Oxford)* 2018;**57**:i4–i11.
- Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. *Circulation* 2015;**132**:1395–1403.
- Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? *Circulation* 2020;**141**:787–789.
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;**377**:1119–1131.
- Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;**391**:319–328.
- Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Gregoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dube MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Leloir J. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Eur Heart J Qual Care Clin Outcomes*. 2020;qcaa045.
- Nidorf SM, Fiolet ATL, Eikelboom JW, Schut A, Opstal TSJ, Bax WA, Budgeon CA, Tijssen JGP, Mosterd A, Cornel JH, Thompson PL; LoDoCo2 Investigators. The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. *Am Heart J* 2019;**218**:46–56.